Clinical applications of bioactive milk components

Nutrition Reviews

Volumn 73, Issue 7, 2015, Pages 463-476

  Hill, David R ^a,b   Newburg, David S ^a  

^a BOSTON COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antimicrobial; Human milk; Prebiotics; Translational research

Indexed keywords

ALPHA LACTALBUMIN; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CASEIN; CYTOKINE; GALACTOSE OLIGOSACCHARIDE; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; LACTOFERRIN; OLIGOSACCHARIDE; PEPTIDE; POLYSACCHARIDE; PREBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; LACTALBUMIN;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BOVINE; BREAST MILK; CANCER CHEMOTHERAPY; CELLS; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COLOSTRUM; CROHN DISEASE; DAIRY PRODUCT; DIARRHEA; ENTERIC FEEDING; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INFECTION; LARGE SCALE PRODUCTION; LUNG CANCER; MYCOSIS; NEOPLASM; NONHUMAN; REMISSION; RESPIRATORY TRACT INFECTION; SEPSIS; TUMOR GROWTH; ANIMAL; CHEMISTRY; IMMUNOLOGY; MILK; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR CELL LINE;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CASEINS; CATTLE; CELL LINE, TUMOR; CROHN DISEASE; HUMANS; LACTALBUMIN; LACTOFERRIN; MILK; MILK, HUMAN; OLIGOSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84946555960     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nuv009     Document Type: Article

References (154)

1. Ip S, Chung M, Raman G, et al. Breastfeeding and Maternal and Infant Health Outcomes in Developed countries. Rockville, MD: Agency for Healthcare Research and Quality; 2002. Evidence Report/Technology Assessment no. 153.
2. Howie PW, Forsyth JS, Ogston SA, et al. Protective effect of breast feeding against infection. BMJ. 1990;300:11-16.
3. Klement E, Cohen RV, Boxman J, et al. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004;80: 1342-1352.
4. Wu T-C, Chen P-H. Health consequences of nutrition in childhood and early infancy. Pediatr Neonatol. 2009;50:135-142.
5. Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920.
6. Palmer C, Bik EM, DiGiulio DB, et al. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5:e177. doi:10.1371/journal.pbio.0050177.
7. Nanthakumar N, Meng D, Goldstein AM, et al. The mechanism of excessive intestinal inflammation in necrotizing enterocolitis: an immature innate immune response. PLoS One. 2011;6:e17776. doi: 10.1371/journal.pone.0017776.
8. Sisk PM, Lovelady CA, Dillard RG, et al. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol. 2007;27:428-433.
9. Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res. 2007;61:2-8.
10. Hanson, LA. Comparative immunological studies of the immune globulins of human milk and of blood serum. Int Arch Allergy Appl Immunol. 1961;18:241-267.
11. Abbas A, Lichtman AH, Pillai S. Cellular and Molecular Immunology. Philadelphia, PA: Saunders Elsevier; 2007.
12. Tawfeek HI, Najim NH, Al-Mashikhi S. Efficacy of an infant formula containing anti-Escherichia coli colostral antibodies from hyperimmunized cows in preventing diarrhea in infants and children: a field trial. Int J Infect Dis. 2003;7:120-128.
13. Otto W, Najnigier B, Stelmasiak T, et al. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol. 2011;46: 862-868.
14. Mitra AK, Mahalanabis D, Ashraf H, et al. Hyperimmune cow colostrum reduces diarrhoea due to rotavirus: a double-blind, controlled clinical trial. Acta Paediatr. 1995;84:996-1001.
15. Martin-Gómez S, Alvarez-Sánchez MA, Rojo-Vázquez FA. Oral administration of hyperimmune anti-Cryptosporidium parvum ovine colostral whey confers a high level of protection against cryptosporidiosis in newborn NMRI mice. J Parasitol. 2005;91:674-678.
16. Steele J, Sponseller J, Schmidt D, et al. Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immunother. 2013;9:1565-1568.
17. Kramski M, Lichtfuss GF, Navis M, et al. Anti-HIV-1 antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol. 2012;42:2771-2781.
18. Ochoa TJ, Chea-Woo E, Baiocchi N, et al. Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. J Pediatr. 2012; 162:349-356.
19. Laffan AM, McKenzie R, Forti J, et al. Lactoferrin for the prevention of post-antibiotic diarrhoea. J Health Popul Nutr. 2011;29:547-51.
20. King JC Jr, Cummings GE, Guo N, et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J Pediatr Gastroenterol Nutr. 2007;44:245-251.
21. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA. 2009;302:1421-1428.
22. Manzoni P, StolfiI, Messner H, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics. 2012;129:116-123.
23. Guntupalli K, Dean N, Morris PE, et al. A phase 2 randomized, double-blind, placebo- controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med. 2013;41:706-716.
24. De Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 2007;102:951-956.
25. Kaito M, Iwasa M, Fujita N, et al. Effect of lactoferrin in patients with chronic hepatitis C: combination therapy with interferon and ribavirin. J Gastroenterol Hepatol. 2007;22:1894-1897.
26. Vitetta L, Coulson S, Beck SL, et al. The clinical efficacy of a bovine lactoferrin/whey protein Ig-rich fraction (Lf/IgF) for the common cold: a double blind randomized study. Complement Ther Med. 2013;21:164-171.
27. Zavaleta N, Figueroa D, Rivera J, et al. Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea. J Pediatr Gastroenterol Nutr. 2007;44:258-264.
28. Parente F, Cucino C, Anderloni A, et al. Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3'sialyllactose sodium salt). A double blind, placebo-controlled clinical study. Helicobacter. 2003;8:252-256.
29. Liu B, Newburg DS. Human milk glycoproteins protect infants against human pathogens. Breastfeed Med. 2013;8:354-362.
30. Brock JH. Lactoferrin-50 years on. Biochem Cell Biol. 2012;90:245-251.
31. Berlutti F, Pantanella F, Natalizi T, et al. Antiviral properties of lactoferrin-a natural immunity molecule. Molecules. 2011;16:6992-7018.
32. Tomita M, Wakabayashi H, Shin K, et al. Twenty-five years of research on bovine lactoferrin applications. Biochimie. 2009;91:52-57.
33. Edde L, Hipolito RB, Hwang FFY, et al. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol. 2001;281: G1140-G1150.
34. Ikeda M, Nozaki A, Sugiyama K, et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res. 2000; 66:51-63.
35. Parodi PW. A role for milk proteins and their peptides in cancer prevention. Curr Pharm Des. 2007;13:813-828.
36. Appelmelk BJ, An YQ, Geerts M, et al. Lactoferrin is a lipid A-binding protein. Infect Immun. 1994;62:2628-2632.
37. Kozu T, Iinuma G, Ohashi Y, et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebocontrolled clinical trial. Cancer Prev Res. 2009;2:975-983.
38. Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebocontrolled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol. 2011;29:4129-4136.
39. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebocontrolled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2011;6:1098-1103.
40. Sun X, Jiang R, Przepiorski A, et al. "Iron-saturated" bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice. BMC Cancer. 2012;12:591. doi: 10.1186/1471-2407-12-591.
41. Tung Y-T, Chen H-L, Yen C-C, et al. Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. J Dairy Sci. 2013;96:2095-2106.
42. Kunz C, RudloffS, Baier W, et al. Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr. 2000;20:699-722.
43. Bode L. Recent advances on structure, metabolism, and function of human milk oligosaccharides. J Nutr. 2006;136:2127-2130.
44. Engfer MB, Stahl B, Finke B, et al. Human milk oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am J Clin Nutr. 2000;71: 1589-1596.
45. Ruiz-Palacios GM. Campylobacter jejuni binds intestinal H(O) antigen (Fucα 1, 2Galβ 1, 4GlcNAc), and fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 2003;278:14112-14120.
46. Morrow AL, Ruiz-Palacios GM, Altaye M, et al. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J Pediatr. 2004; 145:297-303.
47. Cravioto A, Tello A, Villafán H, et al. Inhibition of localized adhesion of enteropathogenic Escherichia coli to HEp-2 cells by immunoglobulin and oligosaccharide fractions of human colostrum and breast milk. J Infect Dis. 1991;163: 1247-1255.
48. Newburg DS, Pickering LK, McCluer RH, et al. Fucosylated oligosaccharides of human milk protect suckling mice from heat-stabile enterotoxin of Escherichia coli. J Infect Dis. 1990;162:1075-1080.
49. Crane JK, Azar SS, Stam A, et al. Oligosaccharides from human milk block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 intestinal cells. J Nutr. 1994;124:2358-2364.
50. Idota T, Kawakami H, Murakami Y, et al. Inhibition of cholera toxin by human milk fractions and sialyllactose. Biosci Biotechnol Biochem. 1995;59:417-419.
51. Coppa GV, Zampini L, Galeazzi T, et al. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediatr Res. 2006;59:377-382.
52. Hong P, Ninonuevo MR, Lee B, et al. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr. 2009;101:482-486.
53. Leach JL, Garber SA, Marcon AA, et al. In vitro and in vivo effects of soluble, monovalent globotriose on bacterial attachment and colonization. Antimicrob Agents Chemother. 2005;49:3842-3846.
54. Simon PM, Goode PL, Mobasseri A, et al. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect Immun. 1997;65:750-757.
55. Mysore JV, Wigginton T, Simon PM, et al. Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound. Gastroenterology. 1999;117:1316-1325.
56. Thomas DW, Greer FR, et al. Probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217-1231.
57. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559-563.
58. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-108.
59. Walker AW, Ince J, Duncan SH, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5:220-230.
60. McDade TW, Metzger MW, Chyu L, et al. Long-term effects of birth weight and breastfeeding duration on inflammation in early adulthood. Proc Biol Sci. 2014; 281:20133116. doi: 10.1098/rspb.2013.3116.
61. Metzger MW, McDade TW. Breastfeeding as obesity prevention in the United States: a sibling difference model. Am J Hum Biol. 2010;22:291-296.
62. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006;118:511-521.
63. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222-227.
64. Kalliomäki M, Kirjavainen P, Eerola E, et al. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol. 2001;107:129-134.
65. Moro G, Minoli I, Mosca M, et al. Dosage-related bifidogenic effects of galactoand fructooligosaccharides in formula-fed term infants. J Pediatr Gastroenterol Nutr. 2002;34:291-295.
66. Arslanoglu S, Moro GE, Boehm G. Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. J Nutr. 2007;137:2420-2424.
67. Westerbeek EAM, van den Berg A, Lafeber HN, et al. The effect of enteral supplementation of a prebiotic mixture of non-human milk galacto-, fructo- and acidic oligosaccharides on intestinal permeability in preterm infants. Br J Nutr. 2011; 105:268-274.
68. Mugambi MN, Musekiwa A, Lombard M, et al. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J. 2012;11:81. doi:10.1186/1475-2891-11-81.
69. Asakuma S, Hatakeyama E, Urashima T, et al. Physiology of consumption of human milk oligosaccharides by infant gut-associated bifidobacteria. J Biol Chem. 2011;286:34583-34592.
70. Yu Z-T, Chen C, Newburg DS. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology. 2013; 23:1281-1292.
71. Yu Z-T, Chen C, Kling DE, et al. The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology. 2013;23:169-177.
72. Bergmann KR, Liu SXL, Tian R, et al. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol. 2013;182:1595-1606.
73. Ward RE, Niñonuevo M, Mills DA, et al. In vitro fermentation of breast milk oligosaccharides by Bifidobacterium infantis and Lactobacillus gasseri. Appl Environ Microbiol. 2006;72:4497-4499.
74. Marcobal A, Barboza M, Sonnenburg ED, et al. Bacteroides in the infant gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe. 2011;10:507-514.
75. Mielcarek C, Romond PC, Romond MB, et al. Modulation of bacterial translocation in mice mediated through lactose and human milk oligosaccharides. Anaerobe. 2011;17:361-366.
76. Hunt KM, Preuss J, Nissan C, et al. Human milk oligosaccharides promote the growth of staphylococci. Appl Environ Microbiol. 2012;78:4763-4770.
77. Underwood MA, Kalanetra KM, Bokulich NA, et al. Prebiotic oligosaccharides in premature infants. J Pediatr Gastroenterol Nutr. 2014;58:352-360.
78. Muthana S, Cao H, Chen X. Recent progress in chemical and chemoenzymatic synthesis of carbohydrates. Curr Opin Chem Biol. 2009;13:573-581.
79. RudloffS, Pohlentz G, Diekmann L, et al. Urinary excretion of lactose and oligosaccharides in preterm infants fed human milk or infant formula. Acta Paediatr. 1996;85:598-603.
80. + T cell proliferation via an IFN-γ and nitric oxide-dependent mechanism. J Immunol. 2001;167:4293-4302.
81. Atochina O, Harn D. LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction. Clin Diagn Lab Immunol. 2005;12: 1041-1049.
82. + cells: a potential mechanism for immune polarization in helminth infections. J Immunol. 2001; 167:5294-5303.
83. Eiwegger T, Stahl B, Schmitt J, et al. Human milk-derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood Tcells in vitro. Pediatr Res. 2004;56:536-540.
84. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012;22:1147-1162.
85. Bode L, Kunz C, Muhly-Reinholz M, et al. Inhibition of monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk oligosaccharides. Thromb Haemost. 2004;92:1402-1410.
86. Bode L, RudloffS, Kunz C, et al. Human milk oligosaccharides reduce plateletneutrophil complex formation leading to a decrease in neutrophil β 2 integrin expression. J Leukoc Biol. 2004;76:820-826.
87. Thompson AM, Bizzarro MJ. Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs. 2008;68:1227-1238.
88. Jantscher-Krenn E, Zherebtsov M, Nissan C, et al. The human milk oligosaccharide disialyllacto-N-tetraose prevents necrotising enterocolitis in neonatal rats. Gut. 2012;61:1417-1425.
89. Varki A, Cummings R, Esko JD, et al. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
90. Frey H, Schroeder N, Manon-Jensen T, et al. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013;280: 2165-2179.
91. Newburg DS, Linhardt RJ, Ampofo SA, et al. Human milk glycosaminoglycans inhibit HIV glycoprotein gp120 binding to its host cell CD4 receptor. J Nutr. 1995; 125:419-424.
92. Coppa GV, Gabrielli O, Buzzega D, et al. Composition and structure elucidation of human milk glycosaminoglycans. Glycobiology. 2010;21:295-303.
93. Hill DR, Rho HK, Kessler SP, et al. Human milk hyaluronan enhances innate defense of the intestinal epithelium. J Biol Chem. 2013;288:29090-29104.
94. Zheng L, Riehl TE, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology. 2009;137:2041-2051.
95. Bollyky PL, Wu RP, Falk BA, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A. 2011;108:7938-7943.
96. Voigt J, Driver VR. Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical wounds, and chronic wounds: a systematic review and metaanalysis of randomized controlled trials. Wound Repair Regen. 2012;20:317-331.
97. Riehl TE, Foster L, Stenson WF. Hyaluronic acid is radioprotective in the intestine through a TLR4 and COX-2-mediated mechanism. Am J Physiol Gastrointest Liver Physiol. 2012;302:G309-G316.
98. Puleo F, Arvanitakis M, Gossum AV, et al. Gut failure in the ICU. Semin Respir Crit Care Med. 2011;32:626-638.
99. Döhler JR, Nebermann L. Bovine colostrum in oral treatment of enterogenic endotoxaemia in rats. Crit Care. 2002;6:536-539.
100. Choi HS, Jung KH, Lee SC, et al. Bovine colostrum prevents bacterial translocation in an intestinal ischemia/reperfusion-injured rat model. J Med Food. 2009;12: 37-46.
101. Playford RJ, Floyd DN, Macdonald CE, et al. Bovine colostrum is a health food supplement which prevents NSAID induced gut damage. Gut. 1999;44: 653-658.
102. Kim JW, Jeon WK, Kim EJ. Combined effects of bovine colostrum and glutamine in diclofenac-induced bacterial translocation in rat. Clin Nutr. 2005;24:785-793.
103. Møller HK, Thymann T, Fink LN, et al. Bovine colostrum is superior to enriched formulas in stimulating intestinal function and necrotising enterocolitis resistance in preterm pigs. Br J Nutr. 2011;105:44-53.
104. Bolke E, Jehle PM, Hausmann F, et al. Preoperative oral application of immunoglobulin- enriched colostrum milk and mediator response during abdominal surgery. Shock. 2002;17:9-12.
105. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13:616-630.
106. Saito S, Yoshida M, Ichijo M, et al. Transforming growth factor-beta (TGF-beta) in human milk. Clin Exp Immunol. 1993;94:220-224.
107. Reeves AA, Johnson MC, Vasquez MM, et al. TGF-β2, a protective intestinal cytokine, is abundant in maternal human milk and human-derived fortifiers but not in donor human milk. Breastfeed Med. 2013;8:496-502.
108. Oddy WH, Rosales F. A systematic review of the importance of milk TGF-beta on immunological outcomes in the infant and young child. Pediatr Allergy Immunol. 2010;21:47-59.
109. Ogawa J, Sasahara A, Yoshida T, et al. Role of transforming growth factor-beta in breast milk for initiation of IgA production in newborn infants. Early Hum Dev. 2004;77:67-75.
110. Rautava S, Lu L, Nanthakumar NN, et al. TGF-β2 induces maturation of immature human intestinal epithelial cells and inhibits inflammatory cytokine responses induced via the NF-κB pathway. J Pediatr Gastroenterol Nutr. 2012;54: 630-638.
111. Verhasselt V, Milcent V, Cazareth J, et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat Med. 2008;14: 170-175.
112. Oz HS, Ray M, Chen TS, et al. Efficacy of a transforming growth factor beta 2 containing nutritional support formula in a murine model of inflammatory bowel disease. J Am Coll Nutr. 2004;23:220-226.
113. Ozawa T, Miyata M, Nishimura M, et al. Transforming growth factor-beta activity in commercially available pasteurized cow milk provides protection against inflammation in mice [in Japanese]. J Nutr. 2009;139:69-75.
114. Penttila I. Effects of transforming growth factor-beta and formula feeding on systemic immune responses to dietary β-lactoglobulin in allergy-prone rats. Pediatr Res. 2006;59:650-655.
115. Oddy WH, McMahon RJ. Milk-derived or recombinant transforming growth factor-beta has effects on immunological outcomes: a review of evidence from animal experimental studies. Clin Exp Allergy. 2011;41:783-793.
116. Day AS, Whitten KE, Lemberg DA, et al. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21:1609-1614.
117. Navas López VM, Blasco Alonso J, Sierra Salinas C, et al. Efficacy of exclusive enteral feeding as primary therapy for paediatric Crohn's disease [in Spanish]. An Pediatría (Barc). 2008;69:506-514.
118. Hartman C, Berkowitz D, Weiss B, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn's disease. Isr Med Assoc J. 2008;10:503-507.
119. Soo J, Malik BA, Turner JM, et al. Use of exclusive enteral nutrition is just as effective as corticosteroids in newly diagnosed pediatric Crohn's disease. Dig Dis Sci. 2013;58:3584-3591.
120. Lionetti P, Callegari ML, Ferrari S, et al. Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J Parenter Enteral Nutr. 2005;29(4 suppl):S173-S175; discussion S175-S178, S184-188.
121. Mossberg A-K, Hun Mok K, Morozova-Roche LA, et al. Structure and function of human α-lactalbumin made lethal to tumor cells (HAMLET)-type complexes. FEBS J. 2010;277:4614-4625.
122. Gustafsson L, Aits S, Onnerfjord P, et al. Changes in proteasome structure and function caused by HAMLET in tumor cells. PloS One. 2009;4:e5229. doi: 10.1371/journal.pone.0005229.
123. Leszek J, Inglot AD, Janusz M, et al. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp (Warsz). 1999; 47:377-385.
124. Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimers Dis. 2004;6: 17-26.
125. Sekiya S, Kobayashi Y, Kita E, et al. Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers [in Japanese]. Nippon Eiyo Shokuryo Gakkaishi. 1992;45:513-517.
126. Townsend RR, McFadden CB, Ford V, et al. A randomized, double-blind, placebocontrolled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Am J Hypertens. 2004;17:1056-1058.
127. Cadée JA, Chang C-Y, Chen C-W, et al. Bovine casein hydrolysate (c12 peptide) reduces blood pressure in prehypertensive subjects. Am J Hypertens. 2007;20: 1-5.
128. Mizuno S, Matsuura K, Gotou T, et al. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr. 2005;94:84-91.
129. Turpeinen AM, Ehlers PI, Kivimäki AS, et al. Ile-Pro-Pro and Val-Pro-Pro tripeptide- containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects. Clin Exp Hypertens. 2011;33:388-396.
130. Ishida Y, Shibata Y, Fukuhara I, et al. Effect of an excess intake of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro in subjects with normal blood pressure, high-normal blood pressure, or mild hypertension. Biosci Biotechnol Biochem. 2011;75:427-433.
131. Håkansson A, Zhivotovsky B, Orrenius S, et al. Apoptosis induced by a human milk protein. Proc Natl Acad Sci U S A. 1995;92:8064-8068.
132. Düringer C, Hamiche A, Gustafsson L, et al. HAMLET interacts with histones and chromatin in tumor cell nuclei. J Biol Chem. 2003;278:42131-42135.
133. Svanborg C, Agerstam H, Aronson A, et al. HAMLET kills tumor cells by an apoptosis- like mechanism-cellular, molecular, and therapeutic aspects. Adv Cancer Res. 2003;88:1-29.
134. Ho CSJ, Rydström A, Trulsson M, et al. HAMLET: functional properties and therapeutic potential. Future Oncol. 2012;8:1301-1313.
135. Fischer W, Gustafsson L, Mossberg A-K, et al. Human α-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res. 2004;64: 2105-2112.
136. Mossberg A-K, Wullt B, Gustafsson L, et al. Bladder cancers respond to intravesical instillation of HAMLET (human α-lactalbumin made lethal to tumor cells). Int J Cancer. 2007;121:1352-1359.
137. Gustafsson L, Leijonhufvud I, Aronsson A, et al. Treatment of skin papillomas with topical α-lactalbumin-oleic acid. N Engl J Med. 2004;350:2663-2672.
138. Gibbs S. Breakthrough in the treatment of warts? Arch Dermatol. 2006;142: 767-768.
139. Saito A, Usui M, Song Y, et al. Secretion of glycosylated α-lactalbumin in yeast Pichia pastoris. J Biochem. 2002;132:77-82.
140. Zhang Y, Luo J, Bi J, et al. Efficient separation of homologous a-lactalbumin from transgenic bovine milk using optimized hydrophobic interaction chromatography. J Chromatogr A. 2010;1217:3668-3673.
141. Hill RL, Brew K. Lactose synthetase. Adv Enzymol Relat Areas Mol Biol. 1975;43: 411-490.
142. Citraro R, Scicchitano F, De Fazio S, et al. Preclinical activity profile of α-lactoalbumin, a whey protein rich in tryptophan, in rodent models of seizures and epilepsy. Epilepsy Res. 2011;95:60-69.
143. Russo E, Scicchitano F, Citraro R, et al. Protective activity of α-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis. Neuroscience. 2012;226:282-288.
144. Kruzel ML, Janusz M, Lisowski J, et al. Towards an understanding of biological role of colostrinin peptides. J Mol Neurosci. 2001;17:379-389.
145. Inglot AD, Janusz M, Lisowski J. Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch Immunol Ther Exp (Warsz). 1996;44:215-224.
146. Popik P, Bobula B, Janusz M, et al. Colostrinin, a polypeptide isolated from early milk, facilitates learning and memory in rats. Pharmacol Biochem Behav. 1999; 64:183-189.
147. Szaniszlo P, German P, Hajas G, et al. New insights into clinical trial for colostrinin in Alzheimer's disease. J Nutr Health Aging. 2009;13:235-241.
148. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol. 2009;41:1261-268.
149. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J Nutr. 2004;134:980S-988S.
150. Conlin PR, Chow D, Miller ER III, et al. The effect of dietary patterns on blood pressure control in hypertensive patients: results from the Dietary Approaches to Stop Hypertension (DASH) trial. Am J Hypertens. 2000;13:949-955.
151. Karaki H, Doi K, Sugano S, et al. Antihypertensive effect of tryptic hydrolysate of milk casein in spontaneously hypertensive rats. Comp Biochem Physiol C. 1990; 96:367-371.
152. Dallas DC, Guerrero A, Khaldi N, et al. A peptidomic analysis of human milk digestion in the infant stomach reveals protein-specific degradation patterns. J Nutr. 2014;144:815-820.
153. Doidge JC, Segal L, Gospodarevskaya E. Attributable risk analysis reveals potential healthcare savings from increased consumption of dairy products. J Nutr. 2012;142:1772-1780.
154. DeFelice SL. The nutraceutical revolution: its impact on food industry R&D. Trends Food Sci Technol. 1995;6:59-61.